| Business Summary | | AVANT
Immunotherapeutics,
Inc.
is
a
biopharmaceutical
company
that
uses
novel
applications
of
immunology
to
prevent
and
treat
diseases
caused
by
both
the
enemy
within
(autoimmune
diseases,
cardiovascular
diseases
and
inflammation)
and
the
enemy
without
(infectious
diseases
and
organ
transplant
rejection).
The
Company's
most
advanced
therapeutic
program
focuses
on
compounds
with
the
potential
to
inhibit
inappropriate
activation
of
the
complement
cascade,
a
vital
part
of
the
body's
immune
defense
system.
AVANT
is
also
developing
a
portfolio
of
oral
vaccines
aimed
at
protecting
travelers
from
diseases
endemic
in
developing
areas,
as
well
as
a
proprietary
therapeutic
vaccine
for
the
management
of
cholesterol.
Through
corporate
collaborations,
the
Company
is
additionally
developing
a
variety
of
infectious
disease
vaccines. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AVANT
Immunotherapeutics,
Inc.
is
a
biotechnology
company
engaged
in
the
discovery,
commercialization
and
development
of
products
that
harness
the
human
immune
response
to
prevent
and
treat
diseases.
For
the
six
months
ended
6/30/01,
revenues
totalled
$1.7
million,
up
from
$308
thousand.
Net
loss
rose
100%
to
$9.7
million.
Results
reflect
higher
development
and
licensing
agreement
revenues,
and
increased
R&D
expenses
related
to
clinical
trials
of
CETi-1
and
TP10. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| J. Barrie Ward, Ph.D., 62 Chairman | -- | -- | Una Ryan, Ph.D, 59 Pres,
CEO, Chief Operating Officer, Director | $335K | -- | Avery Catlin, 52 CFO,
Sr. VP | 204K | -- | Henry Marsh, Jr., Ph.D, 51 VP,
Research | 172K | $8.1K | Alistair Wheeler, M.D., 42 VP,
Medical Affairs | 167K | 52.6K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|